Nov 01, 2023 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
Oct 31, 2023 8:31am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Oct 13, 2023 9:05am EDT Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Sep 21, 2023 9:10am EDT Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Aug 02, 2023 9:10am EDT Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
Jul 28, 2023 9:10am EDT Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study